NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00921414,Mantel Cell Lymphoma Efficacy of Rituximab Maintenance,https://clinicaltrials.gov/study/NCT00921414,,COMPLETED,"Randomized, open-label, phase III study to evaluate the efficacy of rituximab maintenance therapy in patients aged between 18 and 65 years inclusive undergoing first-line treatment for mantle cell lymphoma and exhibiting a response after autologous transplantation.",NO,Mantle Cell Lymphoma,DRUG: Rituximab|OTHER: Watch and wait,"event-free survival (EFS) post Rituximab maintenance therapy, EFS post 4 years after maintenance","duration of PFS of the entire group of patients., Safety/efficacy of maintenance treatment|duration of OS of the entire group of patients, safety/efficacy of treatment|complete, partial and overall response rate after induction with R-DHAP and after ASCT., safety/efficacy of all the treatment",,French Innovative Leukemia Organisation,Lymphoma Study Association,ALL,"ADULT, OLDER_ADULT",PHASE3,299,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,"Manteau 2007 SJ ""LYMA""",2008-09,2008-09,2017-02,2009-06-16,,2018-04-27,"Regional University Hospital, Nantes, 44093, France",
